ESR1 and breast carcinoma: Studies performed in the United States, Canada, and parts of northern Europe have reported that approximately 70% to 80% of patients with breast cancer have HR-positive disease, defined as estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive disease (Huang et al., 2005; Sandoval et al., 2013).